Extended Data Fig. 5: miR-181 levels are predictive of survival length regardless of Riluzole treatment.
From: Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis
Survival by miR-181 levels in untreated patients, from enrollment (A) or onset (B), and in patients that were treated with Riluzole, from enrollment (C) or onset (D). All statistical test were two-sided. N = 248 biologically independent human samples.
